Provided by Tiger Trade Technology Pte. Ltd.

GT Biopharma Inc.

0.5389
+0.04248.54%
Post-market: 0.5301-0.0088-1.63%19:56 EST
Volume:976.38K
Turnover:480.63K
Market Cap:14.36M
PE:-0.16
High:0.5400
Open:0.4800
Low:0.4548
Close:0.4965
52wk High:3.85
52wk Low:0.4011
Shares:26.65M
Float Shares:25.82M
Volume Ratio:0.33
T/O Rate:3.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3776
EPS(LYR):-6.9370
ROE:-356.99%
ROA:-119.47%
PB:4.79
PE(LYR):-0.08

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-JetBlue, VSE, Walt Disney

Reuters
·
Feb 03

GT Biopharma erhält FDA-Zulassung für IND-Antrag zu GTB-5550

Reuters
·
Feb 03

GT Biopharma Inc - Gtb-5550 Phase 1 Trial to Start Mid-2026

THOMSON REUTERS
·
Feb 03

GT Biopharma Announces FDA Clearance of Investigational New Drug (Ind) Application for Gtb-5550 Trike®, a B7-H3-Targeted Natural Killer (Nk) Cell Engager for Solid Tumors Expressing B7-H3

THOMSON REUTERS
·
Feb 03

GT Biopharma submits IND application to U.S. FDA for GTB-5550 TriKE

TIPRANKS
·
Jan 15

GT Biopharma Announces Ind Submission for Gtb-5550 Trike®, a B7-H3-Targeted Natural Killer (Nk) Cell Engager for B7-H3 Expressing Solid Tumor Cancers

THOMSON REUTERS
·
Jan 15

EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment

Benzinga_recent_news
·
Jan 15

GT Biopharma Advances Phase 1 Trial of GTB-3650 for Relapsed Blood Cancers

Reuters
·
Dec 24, 2025

GT Biopharma Faces Nasdaq Delisting Risk Over Minimum Bid Price Compliance

Reuters
·
Nov 27, 2025

GT Biopharma (GTBP) Gets a Buy from Roth MKM

TIPRANKS
·
Nov 18, 2025

GT Biopharma Inc: Holds $2.6M Cash and Cash Equivalents as of Sept 30, Funding Operations Through Q1 2026

THOMSON REUTERS
·
Nov 14, 2025

GT Biopharma Inc: Anticipates Submission of Ind Application for Gtb-5550 in Late December 2025 or in January 2026

THOMSON REUTERS
·
Nov 14, 2025

GT Biopharma files to sell 14.59M shares of common stock for holders

TIPRANKS
·
Oct 25, 2025

BRIEF-GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

Reuters
·
Oct 23, 2025

GT Biopharma Provides Enrollment Update on Gtb-3650 Phase 1 Trial in Patients With Relapsed or Refractory (R/R) Cd33 Expressing Hematologic Malignancies

THOMSON REUTERS
·
Oct 23, 2025

GT Biopharma Inc - Screening Patients for Cohort 4, Dosing to Start Soon

THOMSON REUTERS
·
Oct 23, 2025

GT Biopharma Inc - Advances to Cohort 4 With 10 Ug/Kg/Day Dose

THOMSON REUTERS
·
Oct 23, 2025

GT Biopharma Inc - Next Update Expected in Q1 2026 With Dose Escalation

THOMSON REUTERS
·
Oct 23, 2025

GT Biopharma Provides Enrollment Update on Gtb-3650 Phase 1 Trial in Patients With Relapsed or Refractory (R/R) Cd33 Expressing Hematologic Malignancies

THOMSON REUTERS
·
Oct 08, 2025

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

GlobeNewswire
·
Oct 08, 2025